<DOC>
	<DOCNO>NCT00476216</DOCNO>
	<brief_summary>There direct association cancer thrombosis ( blood clot ) . The purpose study determine best dose antithrombotic ( prevents blood clot ) agent call fondaparinux non-small cell lung cancer ( NSCLC ) . Patients also receive chemotherapy .</brief_summary>
	<brief_title>Fondaparinux ( Arixtra ) With Chemotherapy Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This single center , open-labeled , single arm phase 1 feasibility study patient newly diagnose stage IV NSCLC . To evaluate change biologic parameter measure , two cohort patient receive alter dosing regimen fondaparinux start second cycle chemotherapy . The biologic parameter measure first cycle chemotherapy serve control patient . Chemotherapy consist 3-week cycle carboplatin paclitaxel . The absolute maximum length therapy fondaparinux 3 month , regardless cohort patient assign . This study consist 2 cohort : Cohort 1 : Patients cohort 1 receive standard chemotherapy alone cycle 1 . During subsequent cycle ( 2-4 ) patient receive daily prophylactic dose ( day 1 21 ) fondaparinux . The anticoagulation continue 21 day last course chemotherapy . Cohort 2 : Patients cohort 2 receive standard chemotherapy alone cycle 1 . During subsequent cycle , patient receive therapeutic weight base dose fondaparinux first 2 day chemotherapy cycle follow daily prophylactic dose fondaparinux ( day 3 21 ) next course chemotherapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Histologic cytologic diagnosis NonSmall Cell Lung Cancer . Stage IV NonSmall Cell Lung Cancer . Measurable assessable tumor parameter accord RECIST criterion . ECOG Performance Status 02 . Age 18 79 year ( State Alabama &gt; 18 ) . Adequate hematologic , coagulation , liver renal function , define : Absolute neutrophil count ( ANC ) ≥ 1500/µL Platelet count ≥ 100,000/µL Serum Glutamic Oxaloacetic Transaminase ( SGOT ) /Serum Glutamic Pyruvic Transaminase ( SGPT ) ≤ 2.5 x upper limit normal ≤ 5 x upper limit normal liver metastasis present Total bilirubin value ≤ 1.5 x upper limit normal Serum creatinine value ≤ 1.5 x upper limit normal Normal prothrombin time partial thromboplastin time Fully recover previous surgery ( least 4 week since major surgery ) . Must recover prior radiation therapy ( least 3 week ) . All participant must agree practice approve method birth control ( applicable ) . A negative pregnancy test must document screening period woman childbearing potential . Must provide write informed consent authorization use disclose health information . No prior chemotherapy . Active bleeding disorder . Evidence hemoptysis . Patients bloodtinged bloodstreaked sputum permit study hemoptysis amount less 5 mL blood per episode le 10 mL blood per 24hour period best estimate investigator . Previous history Venous Thromboembolism ( VTE ) within 12 month require active anticoagulation therapy . Concurrent cancer chemotherapy , biologic therapy radiotherapy . Administration investigational drug within 28 day prior administration current therapy . Symptomatic brain metastasis ; patient treat first either whole brain radiation therapy radiosurgery stable disease . Concurrent serious infection . Concomitant severe uncontrolled underlying medical disease unrelated tumor , likely compromise patient safety affect outcome study . History malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy minimum 2 year . Any evidence history hypersensitivity contraindication drug use trial . Psychiatric disorder prevents patient provide informed consent follow protocol instruction . Pregnant lactating woman . Creatinine clearance &lt; 30 mL/min . Patient body weight &lt; 50 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>VTE</keyword>
	<keyword>Arixtra</keyword>
</DOC>